Tags : Rabipur

GSK to Divest its Rabipur and Encepur Vaccines to Bavarian

Shots: GSK to receive $335.9M up front, ~$552.6M milestones including $27.9M as a commercial milestone and $177.5M related to inventory, making the total value as $1B. Bavarian Nordic to get manufacturing and global rights to GSK’s Rabipur/RabAvert and Encepur vaccines. The transaction is expected to be closed on Dec 31, 2019 The vaccines will continue […]Read More